C
Charlotta Ljungman
Researcher at Sahlgrenska University Hospital
Publications - 41
Citations - 4615
Charlotta Ljungman is an academic researcher from Sahlgrenska University Hospital. The author has contributed to research in topics: Heart failure & Dapagliflozin. The author has an hindex of 12, co-authored 31 publications receiving 2394 citations. Previous affiliations of Charlotta Ljungman include University of Gothenburg.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
Mark C. Petrie,Subodh Verma,Kieran F. Docherty,Silvio E. Inzucchi,Inder S. Anand,Jan Belohlavek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andre Dukát,Junbo Ge,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Per Johanson,Peter J. Greasley,David W. Boulton,Olof Bengtsson,Pardeep S. Jhund,John J.V. McMurray +39 more
TL;DR: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.
Journal ArticleDOI
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F. Docherty,Pardeep S. Jhund,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,David L. DeMets,Marc S. Sabatine,Olof Bengtsson,Mikaela Sjöstrand,Anna Maria Langkilde,Akshay S. Desai,Mirta Diez,Jonathan G. Howlett,Tzvetana Katova,Charlotta Ljungman,Eileen O'Meara,Mark C. Petrie,Morten Schou,Subodh Verma,Pham Nguyen Vinh,Scott D. Solomon,John J.V. McMurray +23 more
TL;DR: The benefit of dapagliflozin was consistent regardless of background therapy for HF, with no significant randomized treatment-by-subgroup interaction.
Journal ArticleDOI
Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M Jackson,Pooja Dewan,Inder S. Anand,Jan Bělohlávek,Olof Bengtsson,Rudolf A. de Boer,Michael Böhm,David W. Boulton,Vijay K. Chopra,David L. DeMets,Kieran F. Docherty,Andrej Dukát,Peter J. Greasley,Jonathan G. Howlett,Silvio E. Inzucchi,Tzvetana Katova,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Daniel Lindholm,Charlotta Ljungman,Felipe Martinez,Eileen O'Meara,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Tereshchenko Sn,Subodh Verma,Pardeep S. Jhund,John J.V. McMurray +29 more
TL;DR: The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF, and mean diurtic dose did not differ between the dAPaglif Lozin and placebo groups after randomization.
Journal ArticleDOI
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
Matteo Serenelli,Matteo Serenelli,Michael Böhm,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Scott D. Solomon,David L. DeMets,Olof Bengtsson,Mikaela Sjöstrand,Anna Maria Langkilde,Inder S. Anand,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Mirta Diez,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Subodh Verma,Kieran F. Docherty,Pardeep S. Jhund,John J.V. McMurray +28 more
TL;DR: Dapagliflozin had a small effect on SBP in patients with HFrEF and was superior to placebo in improving outcomes, and well tolerated, across the range of SBP included in DAPA-HF.